Therapy Areas: Oncology
Memo Therapeutics AG Identifies Potent SARS-CoV-2-Neutralizing Antibodies From the Blood of Recovered COVID-19 Patients
4 June 2020 - - Switzerland-based antibody discovery and immune repertoire analysis specialist Memo Therapeutics AG has identified several SARS-CoV-2-specific virus-neutralizing antibodies with the potential for development as a COVID-19 immunotherapy, the company said.

Since March, MTx has selected the most promising donors from hundreds of Swiss COVID-19 patients.

The selection criteria identified patients who had demonstrated a clinical course of COVID-19 indicative of a particularly potent antibody response.

Blood samples were collected from the clinically selected donors and used with MTx's microfluidic DROPZYLLA discovery platform to identify SARS-CoV-2-neutralizing antibodies.

DROPZYLLA enables the generation of complete recombinant human antibody repertoires, preserving all specificities present in each of the patient's B cells.

By processing more than 2m memory B cells from the COVID-19 donors, MTx was able to identify ultra-rare antibodies with superior virus-neutralizing activity within just six weeks of first patient enrollment.

The most potent of these antibodies will now undergo clinical development as a passive immunotherapy for COVID-19, with a clinical proof-of-concept anticipated for Q4 this year.

Memo Therapeutics AG is an innovator in the field of antibody discovery and immune repertoire analysis.

MTx's antibody discovery platform uses robust, simple and fast microfluidic single-cell molecular cloning and screening technologies to enable antibody repertoire mining and antibody discovery at unprecedented speed, efficiency and sensitivity.

The platform captures and preserves entire B-cell repertoires from any donor species and any B-cell type in recombinant form for display using mammalian cells.

The antibody repertoires are subsequently screened in single-cell format using microfluidic screening technology that can assess millions of candidate antibodies directly in functional assays, resulting in recombinant clonal cell lines expressing mAbs with the desired functional properties.

Exploiting its microfluidic single-cell molecular cloning and screening technologies, the company engages in antibody discovery across species and indications for proprietary and partnered projects.

MTx's current pipeline features programs in infectious diseases and immuno-oncology.
Login
Username:

Password: